Exact Sciences ticks higher amid reports HSR for Abbott deal expired
Source: SeekingAlpha
2026-02-06 13:35:52 ET
More on Exact Sciences, Abbott Laboratories
- Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
- Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy
- Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity
- Abbott glucose monitor sensor recall classified as most serious by FDA
- Insider trades: JNJ, Intel, IBM among notable names
Read the full article on Seeking Alpha
For further details see:
Exact Sciences ticks higher amid reports HSR for Abbott deal expired
Exact Sciences Corporation
NASDAQ: EXAS
EXAS Trading
0.27% G/L:
$103.58 Last:
1,132,941 Volume:
$103.53 Open:
EXAS Latest News
March 04, 2026 09:00:00 am
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
March 03, 2026 10:00:00 am
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
February 25, 2026 09:40:00 am
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time
EXAS Stock Data
$19,584,719,665
187,197,642
0.09%
291
N/A
Medical Diagnostics & Screening
Healthcare
US
Madison
